What is Deepcure?
Deepcure operates at the intersection of artificial intelligence and life sciences, leveraging advanced computational models to streamline the drug development lifecycle. By integrating an AI-driven discovery engine with high-throughput automated robotic laboratories, the company addresses critical bottlenecks in traditional pharmaceutical R&D. This dual-pronged technological infrastructure allows Deepcure to rapidly iterate on molecular designs, significantly reducing the time and cost associated with bringing new treatments to market. As a key player in the biotech ecosystem, the company is effectively bridging the gap between digital innovation and biological application, establishing a robust market position as a leader in next-generation drug discovery.
How much funding has Deepcure raised?
Deepcure has raised a total of $104M across 2 funding rounds:
Series A
$40M
Series A
$64M
Series A (2021): $40M with participation from The Morningside Group, TLV Partners, Sapir Venture Partners, and Benon Group
Series A (2024): $64M led by IAG Capital Partners, The Morningside Group, Sapir Venture Partners, and Benon Group
Key Investors in Deepcure
The Morningside Group
Founded in 1986 by the Chan family, this firm provides private equity and venture capital with a focus on deep industry knowledge and social responsibility.
IAG Capital Partners
A venture capital firm operating from Charleston and London that specializes in leading investment rounds from seed to Series C for innovative growth-stage companies.
Sapir Venture Partners
A firm dedicated to empowering entrepreneurs by providing the necessary resources and strategic support to foster innovation and long-term business growth.
What's next for Deepcure?
With the infusion of this major enterprise-level funding, Deepcure is poised to transition into a more aggressive growth phase. The strategic roadmap likely includes expanding its internal pipeline of therapeutic assets and potentially entering into high-value partnerships with established pharmaceutical entities. By leveraging its automated laboratory infrastructure, the company aims to increase the velocity of its discovery cycles, thereby enhancing its competitive advantage in the global biotech landscape. Future milestones will likely focus on clinical validation of its AI-generated candidates and the continued optimization of its proprietary platform to maintain its trajectory as a disruptive force in the pharmaceutical industry.
See full Deepcure company page
